https://scholars.lib.ntu.edu.tw/handle/123456789/567540
標題: | Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes | 作者: | Wang J.-S. Hung Y.-J. Lu Y.-C. Tsai C.-L. WEI-SHIUNG YANG Lee T.-I. Hsiao Y.-C. Sheu W.H.-H. |
關鍵字: | Dipeptidyl peptidase-4 inhibitors; Glycated hemoglobin; Hemoglobin glycation index; Type 2 diabetes; Vildagliptin | 公開日期: | 2018 | 出版社: | Elsevier Ireland Ltd | 卷: | 138 | 起(迄)頁: | 119-127 | 來源出版物: | Diabetes Research and Clinical Practice | 摘要: | Aim: We aimed to investigate the association of difference between observed and predicted glycated hemoglobin (dopHbA1c) and HbA1c reduction after vildagliptin-based oral therapy in patients with type 2 diabetes (T2D). Methods: This was a prospective observational study. Adults ? 20 years old with T2D and HbA1c ≧7% treated with oral anti-diabetic drugs (OADs) were eligible if their OADs were shifted to vildagliptin-based dual oral therapy. Fasting plasma glucose (FPG) and HbA1c were recorded at baseline, week 12, and week 24. To determine baseline dopHbA1c, a predicted HbA1c was calculated by inserting baseline FPG into a regression equation (HbA1c = FPG ? 0.0225 + 4.3806) developed from linear relationship between HbA1c and FPG in an independent cohort of 3239 outpatients with T2D (dopHbA1c = observed HbA1c – predicted HbA1c). Patients were assigned to low (≦0) or high (>0) dopHbA1c group according to their baseline dopHbA1c levels. The study endpoint was changes from baseline to week 24 in HbA1c levels. Results: A total of 1224 patients were enrolled. Patients with a dopHbA1c >0 had a greater HbA1c reduction after vildagliptin-based dual oral therapy than those with a dopHbA1c ≦0 (?1.5 ± 2.0 vs. ?0.4 ± 1.0%, p < 0.001). Baseline dopHbA1c was positively associated with HbA1c reduction from baseline to week 24 (β coefficient 0.883, 95% CI 0.811 to 0.955, p < 0.001), and the association remained significant after adjustment for confounders. Conclusions: In T2D patients with an HbA1c ≧7%, a higher baseline dopHbA1c was associated with a greater HbA1c reduction after shifting to vildagliptin-based dual oral therapy. ? 2018 Elsevier B.V. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042383785&doi=10.1016%2fj.diabres.2018.02.002&partnerID=40&md5=9ffe7c181c80864ce99f7c64fe40eba2 https://scholars.lib.ntu.edu.tw/handle/123456789/567540 |
ISSN: | 0168-8227 | DOI: | 10.1016/j.diabres.2018.02.002 | SDG/關鍵字: | 2,4 thiazolidinedione derivative; hemoglobin A1c; metformin; oral antidiabetic agent; sulfonylurea; vildagliptin; adamantane; antidiabetic agent; dipeptidyl peptidase IV inhibitor; glycosylated hemoglobin; nitrile; pyrrolidine derivative; vildagliptin; adult; age distribution; Article; controlled study; disease duration; female; glucose blood level; human; major clinical study; male; non insulin dependent diabetes mellitus; observational study; open study; population research; prediction; prospective study; sex difference; treatment duration; treatment outcome; treatment response; analogs and derivatives; blood; metabolism; middle aged; Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。